Inhibrx Inc (INBX)
35.01
-0.14
(-0.40%)
USD |
NASDAQ |
Mar 28, 16:00
35.01
0.00 (0.00%)
After-Hours: 20:00
Inhibrx Free Cash Flow (Quarterly): -60.26M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -60.26M |
September 30, 2023 | -55.06M |
June 30, 2023 | -42.62M |
March 31, 2023 | -39.97M |
December 31, 2022 | -30.87M |
September 30, 2022 | -30.82M |
June 30, 2022 | -27.24M |
March 31, 2022 | -27.06M |
December 31, 2021 | -22.89M |
September 30, 2021 | -13.84M |
June 30, 2021 | -22.79M |
Date | Value |
---|---|
March 31, 2021 | -21.66M |
December 31, 2020 | -16.00M |
September 30, 2020 | -14.18M |
June 30, 2020 | -11.67M |
March 31, 2020 | -7.479M |
December 31, 2019 | -12.28M |
September 30, 2019 | -1.484M |
June 30, 2019 | -14.47M |
March 31, 2019 | -5.654M |
June 30, 2018 | -13.52M |
March 31, 2018 | -2.189M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-60.26M
Minimum
Dec 2023
-1.484M
Maximum
Sep 2019
-23.91M
Average
-22.23M
Median
Free Cash Flow (Quarterly) Benchmarks
Johnson & Johnson | 5.804B |
Gilead Sciences Inc | 1.954B |
Outlook Therapeutics Inc | -13.03M |
Axonics Inc | 4.323M |
NovaBay Pharmaceuticals Inc | -0.365M |